Last week, Microsoft Corp revealed an expanded partnership with NVIDIA, leveraging the power of generative AI, cloud computing, and accelerated computing.
As stated in a press release, this joint endeavor sought to combine the extensive scale and computing prowess of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite. The goal was to drive faster innovation and improve patient care within healthcare and life sciences institutions worldwide.
Regarding this collaboration, Peter Durlach, Corporate Vice President of Health & Life Sciences at Microsoft, expressed that Microsoft was extending its longstanding partnership with NVIDIA to equip the healthcare and life sciences sector with Azure’s capabilities and generative AI.
Durlach further stated that this initiative aimed to open up new frontiers in clinical research, pharmaceutical innovation, and global patient care.
The press release indicated that the collaboration provided opportunities for healthcare providers, pharmaceutical companies, biotechnology firms, and medical device developers to innovate quickly in clinical research, drug discovery, and care delivery, resulting in improved efficiency and effectiveness.
Speaking on this matter, Kimberly Powell, Vice President of Healthcare at NVIDIA, remarked that the merging of AI, cloud computing, and healthcare was poised to revolutionize patient care.
A notable aspect of this partnership was the expedited drug discovery process achieved through NVIDIA BioNeMo, hosted on NVIDIA DGX Cloud and facilitated by Microsoft Azure.
BioNeMo acts as a generative AI platform, streamlining and accelerating model training on proprietary data, thereby speeding up AI-driven drug discovery initiatives. This progress holds the potential for quicker availability of life-saving treatments for patients worldwide.
Furthermore, the partnership sought to improve clinical research and healthcare delivery by utilizing AI diagnostic technology based on medical imaging.
Azure, NVIDIA MONAI (Medical Open Network for AI), and the Nuance Precision Imaging Network are combined to enable the development, validation, deployment, and evaluation of medical imaging AI models on a large scale. This allows developers to construct high-performance medical imaging AI models. Further, healthcare providers can deploy a single platform for running a wide array of third-party AI models integrated into clinical workflows.
In partnership with NVIDIA and researchers at the University of Wisconsin School of Medicine and Public Health, Flywheel is leading the charge to transform medical imaging research using AI technology. This initiative integrates research insights, imaging data platforms, and NVIDIA MONAI microservices to facilitate automated anatomical study classifications. This has marked a substantial stride towards AI-powered medical advancements.
The collaboration between Microsoft, NVIDIA, and SOPHiA GENETICS aims to expedite genomics analysis by leveraging the SOPHiA DDM Platform on Azure, powered by NVIDIA Parabricks. This integrated solution simplifies whole-genome analytical procedures, delivering actionable insights for healthcare institutions globally.
Microsoft will additionally offer a range of NVIDIA healthcare microservices on Azure AI. This endeavor was designed to enhance inference and fine-tuning processes, fostering innovation and reshaping patient care through interdisciplinary collaboration.
